These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 35176563)
1. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia. Feng Z; Hu Z; Li L; Yu M; Zhang Y; Jing P; Xu X; Wu J; Hu Y; Xu X Front Pharmacol; 2024; 15():1298061. PubMed ID: 38327987 [No Abstract] [Full Text] [Related]
2. Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D Vojtechova I; Tuckova K; Juza R; Stuchlik A; Kelemen E; Korabecny J; Soukup O; Petrasek T Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110819. PubMed ID: 37379895 [TBL] [Abstract][Full Text] [Related]
3. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167 [TBL] [Abstract][Full Text] [Related]
4. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Gründer G Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978 [TBL] [Abstract][Full Text] [Related]
6. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders. De Deurwaerdère P Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339 [TBL] [Abstract][Full Text] [Related]
7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]